# Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage

> **NCT02560532** · PHASE2 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 25 (actual)

## Conditions studied

- Aneurysmal Subarachnoid Hemorrhage

## Interventions

- **DRUG:** Clazosentan

## Key facts

- **NCT ID:** NCT02560532
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-01
- **Primary completion:** 2017-05-02
- **Final completion:** 2017-05-02
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02560532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02560532, "Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02560532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*